39.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Precedente Chiudi:
$39.86
Aprire:
$39.04
Volume 24 ore:
685.09K
Relative Volume:
1.71
Capitalizzazione di mercato:
$2.52B
Reddito:
-
Utile/perdita netta:
$-80.77M
Rapporto P/E:
-30.76
EPS:
-1.27
Flusso di cassa netto:
$-80.80M
1 W Prestazione:
-3.71%
1M Prestazione:
-6.44%
6M Prestazione:
-22.51%
1 anno Prestazione:
-22.22%
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Nome
Moonlake Immunotherapeutics
Settore
Industria
Telefono
41 41 510 8022
Indirizzo
DORFSTRASSE 29, ZUG
Confronta MLTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
MLTX
Moonlake Immunotherapeutics
|
39.07 | 2.52B | 0 | -80.77M | -80.80M | -1.27 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
2025-01-17 | Aggiornamento | Goldman | Neutral → Buy |
2024-11-05 | Ripresa | Wedbush | Outperform |
2024-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2024-06-25 | Iniziato | Oppenheimer | Outperform |
2024-04-02 | Iniziato | Goldman | Neutral |
2024-02-15 | Iniziato | Wolfe Research | Outperform |
2023-12-08 | Iniziato | Citigroup | Buy |
2023-11-02 | Iniziato | Stifel | Buy |
2023-09-14 | Downgrade | Bryan Garnier | Buy → Neutral |
2023-08-31 | Iniziato | Needham | Buy |
2023-06-15 | Iniziato | Barclays | Equal Weight |
2023-05-01 | Iniziato | Guggenheim | Buy |
2023-03-22 | Iniziato | Wedbush | Outperform |
2023-03-09 | Iniziato | BTIG Research | Buy |
2023-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
2023-02-02 | Iniziato | Bryan Garnier | Buy |
2022-11-11 | Iniziato | Jefferies | Buy |
2022-08-25 | Iniziato | SVB Leerink | Outperform |
2022-07-21 | Iniziato | H.C. Wainwright | Buy |
2022-07-07 | Iniziato | Cowen | Outperform |
Mostra tutto
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
MoonLake’s 37% decline validates InvestingPro’s overvaluation warning By Investing.com - Investing.com India
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by PNC Financial Services Group Inc. - Defense World
BTIG maintains Moonlake stock Buy rating and $81 target By Investing.com - Investing.com Australia
MoonLake Immunotherapeutics’ Sonelokimab Positioned as Leading Treatment for Hidradenitis Suppurativa Amidst Weak JAK Inhibitor Competition - TipRanks
BTIG maintains Moonlake stock Buy rating and $81 target - Investing.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Coverage Initiated by Analysts at Royal Bank of Canada - Defense World
MoonLake earns new Outperform at RBC Capital Markets on lead drug - MSN
RBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform Recommendation - Nasdaq
MoonLake stock earns new Outperform at RBC (MLTX:NASDAQ) - Seeking Alpha
Why MoonLake Immunotherapeutics Shares Are Rising - TipRanks
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN
Guggenheim maintains $80 target on Moonlake Immunotherapeutics stock - Investing.com
MoonLake Immunotherapeutics initiated with an Outperform at RBC Capital - TipRanks
Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target - MarketScreener
RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com
MoonLake Immunotherapeutics: Advancing Sonelokimab with Promising Phase III VELA Program and Favorable Market Positioning - TipRanks
MoonLake Immunotherapeutics Advances Clinical Trials in 2024 - TipRanks
MoonLake’s CEO on its looming mid-year pivotal readout in skin disease - Endpoints News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Victory Capital Management Inc. - Defense World
Cowen maintains Buy on Moonlake Immunotherapeutics stock By Investing.com - Investing.com Australia
Cowen maintains Buy on Moonlake Immunotherapeutics stock - Investing.com India
MoonLake Immunotherapeutics: Promising Prospects for Sonelokimab in Inflammatory Diseases - TipRanks
Why MoonLake Immunotherapeutics is the Dark Horse Pharma Stock to Watch in 2025 - DSA
Optimistic Outlook for MoonLake Immunotherapeutics: Promising Developments and Market Opportunities for Sonelokimab - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
The Goldman Sachs Group Cuts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $73.00 - Defense World
Brokers Offer Predictions for MLTX Q2 Earnings - MarketBeat
MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Thursday - MarketBeat
(MLTX) Technical Pivots with Risk Controls - Stock Traders Daily
The Goldman Sachs Group Has Lowered Expectations for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price - MarketBeat
MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Needham & Company LLC Increases MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $66.00 - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Earnings Results, Misses Expectations By $0.09 EPS - MarketBeat
MoonLake Immunotherapeutics: Buy Rating Backed by Promising SLK Data and Strong Financial Position - TipRanks
MoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on Thursday - Defense World
Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Programs and Market Potential - TipRanks
Moonlake Immunotherapeutics Faces Hurdles in Commercializing SLK Despite Potential Approvals - TipRanks
MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 Trials and Robust Financial Position - TipRanks
Buy Rating for MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments - TipRanks
MoonLake Immunotherapeutics: Promising Future with Strong Financial Position and Clinical Advancements - TipRanks
MoonLake Immunotherapeutics reports Q4 EPS (72c), consensus (59c) - TipRanks
MoonLake Immunotherapeutics Q4 Loss Widens -February 26, 2025 at 07:53 am EST - Marketscreener.com
Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q4 Loss of $-0.72 a Share, vs. FactSet Est of $-0.59 Loss - Marketscreener.com
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
MoonLake Immunotherapeutics SEC 10-K Report - TradingView
Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now? - Insider Monkey
This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - simplywall.st
MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey
Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):